Home - News ( United States | United Kingdom | Italy | Germany ) - Football scores

Showing content from https://pubmed.ncbi.nlm.nih.gov/12948281/ below:

Comparison of HPV-based assays with Papanicolaou smears for cervical cancer screening in Morelos State, Mexico

Comparative Study

Affiliations

• ¹ Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, México. jsalme@prodigy.net.mx

• PMID: 12948281
• DOI: 10.1023/a:1024806707399

Item in Clipboard

Comparative Study

Jorge Salmerón et al. Cancer Causes Control. 2003 Aug.

• ¹ Unidad de Investigación Epidemiológica y en Servicios de Salud, Instituto Mexicano del Seguro Social, Morelos, México. jsalme@prodigy.net.mx

• PMID: 12948281
• DOI: 10.1023/a:1024806707399

Item in Clipboard

Objective: To compare the performance of human papillomavirus (HPV) assays with conventional Pap cytology for cervical cancer (CC) screening in Mexico.

Methods: Pap smears, self-collected vaginal specimens (SS) for HPV testing, and clinician-collected cervical specimens (CS) for HPV testing were obtained from 7868 women, aged 15-85 years old, attending CC screening at the Mexican Institute of Social Security (IMSS) between May and October, 1999. SS and CS specimens were screened for oncogenic HPV DNA by Hybrid Capture 2. Women who received cytological interpretations of atypical squamous cells of undetermined significance (ASCUS), and/or a positive HPV test were referred for colposcopy and histologic studies. The relative estimates for sensitivity, specificity and predictive values of each test were calculated using histological diagnoses of cervical intraepithelial neoplasia (CIN) grades 2 or 3, or CC histological diagnosis.

Results: Oncogenic HPV detection rate was 11.6% for SS, and 9.3% for CS. Pap smear abnormalities were observed in 2.4% of the women. Of 1147 women who had at least one abnormal test result, 88.5% underwent colposcopy, and 101 biopsy-confirmed CIN2/3 or cancer cases were identified. The relative sensitivity estimates for the Pap test, SS and CS were 59.4% (95% CI: 49.2-68.9), 71.3% (95% CI: 61.3-79.6), and 93.1% (95% CI: 85.8-96.9), respectively, while the specificities were 98.3% (95% CI: 98.0-98.6), 89.2% (95% CI: 88.5-89.9), and 91.8% (95% CI: 91.2-92.4), respectively. The positive predictive values of Pap, SS and CS were 36.1, 9.1 and 14.9, the colposcopy referrals needed to detect a case of CIN2/3 or cancer were 2.8, 11.0 and 6.7, respectively.

Discussion: Both HPV assays detected more cases of CIN2/3 or CC than Pap cytology alone. However, the HPV assays increased the number of colposcopy referrals. Our study suggests that HPV testing could be an effective way to improve the performance of CC screening.

PubMed Disclaimer

• Cytology versus HPV testing for cervical cancer screening in the general population.

  Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. Koliopoulos G, et al. Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. doi: 10.1002/14651858.CD008587.pub2. Cochrane Database Syst Rev. 2017. PMID: 28796882 Free PMC article. Review.

• Evaluation of human papillomavirus testing in primary screening for cervical abnormalities: comparison of sensitivity, specificity, and frequency of referral.

  Kulasingam SL, Hughes JP, Kiviat NB, Mao C, Weiss NS, Kuypers JM, Koutsky LA. Kulasingam SL, et al. JAMA. 2002 Oct 9;288(14):1749-57. doi: 10.1001/jama.288.14.1749. JAMA. 2002. PMID: 12365959

• Identifying women with cervical neoplasia: using human papillomavirus DNA testing for equivocal Papanicolaou results.

  Manos MM, Kinney WK, Hurley LB, Sherman ME, Shieh-Ngai J, Kurman RJ, Ransley JE, Fetterman BJ, Hartinger JS, McIntosh KM, Pawlick GF, Hiatt RA. Manos MM, et al. JAMA. 1999 May 5;281(17):1605-10. doi: 10.1001/jama.281.17.1605. JAMA. 1999. PMID: 10235153

• A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.

  Lazcano-Ponce E, Lörincz AT, Salmerón J, Fernández I, Cruz A, Hernández P, Mejia I, Hernández-Avila M. Lazcano-Ponce E, et al. Cancer Causes Control. 2010 Oct;21(10):1693-700. doi: 10.1007/s10552-010-9598-2. Epub 2010 Jul 9. Cancer Causes Control. 2010. PMID: 20617376

• Accuracy of human papillomavirus testing on self-collected versus clinician-collected samples: a meta-analysis.

  Arbyn M, Verdoodt F, Snijders PJ, Verhoef VM, Suonio E, Dillner L, Minozzi S, Bellisario C, Banzi R, Zhao FH, Hillemanns P, Anttila A. Arbyn M, et al. Lancet Oncol. 2014 Feb;15(2):172-83. doi: 10.1016/S1470-2045(13)70570-9. Epub 2014 Jan 14. Lancet Oncol. 2014. PMID: 24433684 Review.

• Prevention of Cervical Cancer: Guideline of the DGGG and the DKG (S3 Level, AWMF Register Number 015/027OL, December 2017) - Part 2 on Triage, Treatment and Follow-up.

  Hillemanns P, Friese K, Dannecker C, Klug S, Seifert U, Iftner T, Hädicke J, Löning T, Horn L, Schmidt D, Ikenberg H, Steiner M, Freitag U, Siebert U, Sroczynski G, Sauerbrei W, Beckmann MW, Gebhardt M, Friedrich M, Münstedt K, Schneider A, Kaufmann A, Petry KU, Schäfer APA, Pawlita M, Weis J, Mehnert A, Fehr M, Grimm C, Reich O, Arbyn M, Kleijnen J, Wesselmann S, Nothacker M, Follmann M, Langer T, Jentschke M. Hillemanns P, et al. Geburtshilfe Frauenheilkd. 2019 Feb;79(2):160-176. doi: 10.1055/a-0828-7722. Epub 2019 Feb 18. Geburtshilfe Frauenheilkd. 2019. PMID: 30792546 Free PMC article.

• Cytology versus HPV testing for cervical cancer screening in the general population.

  Koliopoulos G, Nyaga VN, Santesso N, Bryant A, Martin-Hirsch PP, Mustafa RA, Schünemann H, Paraskevaidis E, Arbyn M. Koliopoulos G, et al. Cochrane Database Syst Rev. 2017 Aug 10;8(8):CD008587. doi: 10.1002/14651858.CD008587.pub2. Cochrane Database Syst Rev. 2017. PMID: 28796882 Free PMC article. Review.

• Detecting cervical precancer and reaching underscreened women by using HPV testing on self samples: updated meta-analyses.

  Arbyn M, Smith SB, Temin S, Sultana F, Castle P; Collaboration on Self-Sampling and HPV Testing. Arbyn M, et al. BMJ. 2018 Dec 5;363:k4823. doi: 10.1136/bmj.k4823. BMJ. 2018. PMID: 30518635 Free PMC article.

• Assessment of high-risk human papillomavirus infections using clinician- and self-collected cervical sampling methods in rural women from far western Nepal.

  Johnson DC, Bhatta MP, Smith JS, Kempf MC, Broker TR, Vermund SH, Chamot E, Aryal S, Lhaki P, Shrestha S. Johnson DC, et al. PLoS One. 2014 Jun 30;9(6):e101255. doi: 10.1371/journal.pone.0101255. eCollection 2014. PLoS One. 2014. PMID: 24978811 Free PMC article.

• Evaluating the Performance of Hybrid Capture 2 Test as a Primary Screening Test from Studies Conducted in Low and Middle-Income Country Settings- Special Focus India.

  Anand KV, Pimple SA, Bhattacharjee A, Mishra GA, Shastri SS. Anand KV, et al. Asian Pac J Cancer Prev. 2021 Aug 1;22(8):2709-2716. doi: 10.31557/APJCP.2021.22.8.2709. Asian Pac J Cancer Prev. 2021. PMID: 34452578 Free PMC article.

RetroSearch is an open source project built by @garambo | Open a GitHub Issue

Search and Browse the WWW like it's 1997 | Search results from DuckDuckGo

HTML: 3.2 | Encoding: UTF-8 | Version: 0.7.3